pre-IPO PHARMA

COMPANY OVERVIEW

Verge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGE™, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry’s most advanced all-in-human AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.vergegenomics.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS

agent-capital als-investment-fund

PRESS RELEASES


Nov 14, 2022

Alice Zhang, CEO and Co-founder of Verge Genomics, Recognized Today by Both Fortune and Fierce Biotech as a Pioneer in AI-Driven Drug Discovery


Oct 31, 2022

Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, a Novel Therapeutic for Amyotrophic Lateral Sclerosis


Oct 17, 2022

Verge Genomics Appoints John Applegate as Chief Financial Officer


Oct 12, 2022

Verge Genomics Honored by Goldman Sachs for Entrepreneurship


Sep 12, 2022

Fierce Biotech Names Verge Genomics a 2022 “Fierce 15” Biotech Company


For More Press Releases


Google Analytics Alternative